Question · asked by 1 review

Keratinocyte GF 50 mg vs Keratinocyte GF 25 mg: Oral mucositis (moderate to severe)

Population
Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Intervention
Keratinocyte GF 50 mg
Comparison
Keratinocyte GF 25 mg
Outcome
Oral mucositis (moderate to severe)

Keratinocyte GF 50 mg showed no clear difference in oral mucositis (moderate to severe) compared with keratinocyte GF 25 mg; GRADE not reported.

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Keratinocyte GF 50 mg vs Keratinocyte GF 25 mg
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies · Median 28 days
Keratinocyte GF 50 mg showed no clear difference in oral mucositis (moderate to severe) compared with keratinocyte GF 25 mg; GRADE not reported.
Interventions for preventing oral mucositis for patients with cancer receiving treatment (2011) · Cochrane All outcomes
RR 0.78 [0.4, 1.49]1 study · 28 participantsGRADE not reported

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Interventions for preventing oral mucositis for patients with cancer receiving treatment
2011 · Cochrane All outcomes
2011-02Not listedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.